A Study Comparing Begelomab Versus Other Treatments Options For The Treatment Of Patients With Steroid Refractory Acute Graft Versus Host Disease (SR-aGvHD) Using A Matched Paired Analysis.

Trial Profile

A Study Comparing Begelomab Versus Other Treatments Options For The Treatment Of Patients With Steroid Refractory Acute Graft Versus Host Disease (SR-aGvHD) Using A Matched Paired Analysis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Begelomab (Primary) ; Alpha 1-antitrypsin; Antithymocyte globulin; Cyclophosphamide; Etanercept; Mycophenolate; Sirolimus; Steroids
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jan 2017 New trial record
    • 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top